CERo Therapeutics Advances Phase 1 Trial with Third Patient in Cohort 2
Event summary
- CERo Therapeutics dosed the third patient in Cohort 2 of its Phase 1 CER-1236 trial, marking the sixth patient overall.
- The trial has expanded to include earlier forms of myelodysplastic syndrome (MDS) and myelofibrosis (MF).
- No cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported.
- One patient with inv(3) AML achieved 72 consecutive days of platelet transfusion independence at the lowest dose level.
The big picture
CERo Therapeutics is advancing its proprietary Chimeric Engulfment Receptor T cell (CER-T) technology, aiming to differentiate itself from traditional CAR-T therapies. The expansion into MDS and MF indicates a strategic shift towards addressing broader hematologic malignancies with significant unmet medical needs.
What we're watching
- Trial Expansion
- Whether the inclusion of earlier MDS and MF patients will accelerate clinical validation.
- Safety Profile
- How the absence of CRS and ICANS impacts future dose escalation and regulatory approvals.
- Clinical Efficacy
- The pace at which CER-1236 demonstrates measurable clinical responses in expanded patient populations.
Related topics